Treats serious infections due to susceptible strains of Gram-negative bacteria, including…. ANDA 63315, held by Hikma. Amikacin Sulfate.
As of Nov 16, 2026, ANDA 63315 (Amikacin Sulfate), held by Hikma, was first approved by FDA on Apr 11, 1994, with 6 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Amikacin Sulfate Injection is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli, species of indole-positive and indole-negative Proteus, Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 11, 1994 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Amikacin SulfateEQ 250MG BASE/ML · injectable;injection | Amikacin Sulfate | Rx |
| Mar 21, 2024 | Supplement 23Labeling · Standard review | Approved | None posted |
| May 11, 2016 | Supplement 15Labeling · Standard review | Approved | None posted |
| May 11, 2016 | Supplement 16Labeling · Standard review | Approved | None posted |
| Nov 20, 2012 | Supplement 12Labeling · Standard review | Approved | None posted |
| Apr 3, 2001 | Supplement 2Manufacturing | Approved | None posted |
| Aug 8, 1997 | Supplement 1Manufacturing | Approved | None posted |
| Apr 11, 1994 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters